Regulation of RAS-GTPase Activity by Oncofetal Chondroitin Sulfate (Chondroitin 4-Sulfate) and Arylsulfatase B

Cancer often begins with a single broken switch inside a cell. This switch is a protein called RAS, which acts like a gatekeeper for cell growth. When the gate is closed, the cell stays quiet; when it is open, the cell receives the signal to divide. In many aggressive tumors, this gate gets stuck in the open position, causing cells to multiply uncontrollably. For decades, scientists have struggled to fix this broken switch because the protein's shape makes it nearly impossible for standard drugs to grab hold of it. While recent medicines have learned to target specific broken versions of this switch, they do not work for every patient, and the cancer often finds a way to resist them. This has left researchers searching for a different strategy: instead of trying to patch the broken switch directly, they are looking for ways to turn off the signal that tells the switch to stay open in the first place.

A new study from researchers at the Jesse Brown VA Medical Center explores a surprising path to solving this problem. They discovered that the activity of the RAS switch is deeply connected to a sugar molecule found on the surface of cells, known as chondroitin 4-sulfate. This sugar is part of a larger family of molecules that coat our cells, acting somewhat like a protective blanket or a communication network. The researchers focused on an enzyme called Arylsulfatase B, which acts like a pair of molecular scissors. Its job is to trim a specific chemical tag, a sulfate group, off the chondroitin 4-sulfate sugar. When this enzyme works normally, it keeps the sugar in a specific state. But when the enzyme is missing or silenced, the sugar accumulates with too many sulfate tags attached.

The team set out to see what happens to the RAS switch when this sugar balance is disturbed. They worked with human melanoma cells, which are a type of skin cancer, as well as normal skin cells and cells from the intestine. In the lab, they used a precise method to silence the gene that makes the Arylsulfatase enzyme. As they expected, silencing the enzyme caused the chondroitin 4-sulfate sugar to build up. What they found next was striking: the RAS switch, which should have been quiet, suddenly flipped to its active state. The activity of this switch jumped dramatically, increasing by as much as 222 percent in some cases. Conversely, when the researchers added a manufactured version of the enzyme back into the cells, the sugar levels dropped, and the RAS switch activity fell by more than half. This pattern held true not just in a dish of cells, but also in mice with melanoma tumors, where treating the animals with the enzyme reduced the activity of the RAS switch in their lung and skin tumors.

To understand how a sugar molecule could control a protein switch, the researchers traced the steps in between. They found that the buildup of the sulfated sugar changes how other molecules in the cell interact. Specifically, a protein called galectin-3, which usually sticks to the sugar, finds it harder to bind when the sugar is overloaded with sulfate tags. This leaves galectin-3 floating freely in the cell. This free-floating protein then triggers a chain reaction that increases the production of another protein called EGFR. EGFR is a receptor on the cell surface that acts like an antenna, listening for growth signals. When there is more of this antenna, the cell becomes hyper-sensitive to growth signals, which in turn forces the RAS switch to stay open. The researchers confirmed this by showing that if they blocked the production of EGFR or stopped the signaling steps that lead to it, the surge in RAS activity disappeared, even when the sugar levels were high.

The study also looked at how the cell makes these sulfate tags in the first place. The tags are added by enzymes called sulfotransferases, which rely on a universal fuel source called PAPS. When the researchers reduced the amount of this fuel source, the overall activity of the RAS switch dropped slightly, suggesting that the cell's ability to sulfate its sugars is directly linked to how hard the RAS switch works. Interestingly, they found that not all sugar-modifying enzymes had the same effect. Removing the ability to add a different type of tag, a six-sulfate group, did not change the RAS switch at all. This confirmed that the specific four-sulfate tag on the chondroitin sugar is the critical factor driving the change.

The connection between the sugar and the switch is so strong that the researchers found a near-perfect match between the amount of chondroitin 4-sulfate in the cells and the activity of the RAS switch. As the sugar levels rose, the switch activity rose in lockstep. They also tested a protein called VAR2CSA, which is known to bind tightly to this specific type of sugar. They found that when the sugar levels were high due to the lack of the enzyme, VAR2CSA bound to it much more strongly, further confirming that the sugar structure had changed in a way that altered its interactions with other proteins.

This work suggests a new way to think about controlling cancer growth. Instead of trying to force the broken RAS switch to close, it may be possible to lower the levels of the specific sugar that keeps it open. By restoring the activity of the Arylsulfatase enzyme or blocking the production of the sulfated sugar, it might be possible to turn down the volume on the growth signals that drive tumors. The researchers note that while new drugs are being developed to target specific mutations in the RAS protein, this approach offers a different angle that could work across many different types of cancer, regardless of the specific mutation present. The findings point to a biological pathway where the chemistry of sugar molecules on the cell surface can dictate the behavior of the most famous drivers of cancer, offering a fresh target for future therapies.